Compare APMD & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APMD | STK |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.5M | 921.0M |
| IPO Year | 2026 | 2009 |
| Metric | APMD | STK |
|---|---|---|
| Price | $16.65 | $49.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $50.33 | N/A |
| AVG Volume (30 Days) | ★ 346.0K | 42.6K |
| Earning Date | 11-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.88 | $32.50 |
| 52 Week High | $35.29 | $58.46 |
| Indicator | APMD | STK |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 43.81 |
| Support Level | $16.43 | $47.02 |
| Resistance Level | $19.83 | $53.92 |
| Average True Range (ATR) | 1.52 | 1.63 |
| MACD | 0.28 | -0.14 |
| Stochastic Oscillator | 46.55 | 31.96 |
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.